Phase 2 N=55 T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
HER2-positive Breast Cancer · Breast Cancer · Breast Cancer Stage
Primary: Estimate Progression-free Survival — 16.9; 8.3 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=21 Effects of Sandostatin LAR® in Acromegaly
Acromegaly
Primary: IGF-1 Level on Sandostatin LAR — 336; 186; 487 ng/mL — p=<0.05
Phase 1 N=48 Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid
Multi-drug Resistant Tuberculosis
Primary: Relative Bioavailability - Cmax — 2170; 1180; 1850; 1090 ng/mL — p=0.0001
N/A N=74 OCS Liver PROTECT Continued Access Protocol
Liver Transplant
Primary: Participants With Early Liver Allograft Dysfunction (EAD) — 19 Participants
Phase 2 N=243 A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease
Diabetic Nephropathies
Primary: Change From Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in 10-hour Urine After 20 Weeks of Trial Treatment — -0.069; -0.029; -0.217; 0.034…
Phase 2 N=175 A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Solid Tumors
Primary: Overall Response Rate (ORR) — 6; 1; 15; 0 Participants
N/A N=3,332 A Clinical Risk Score for Early Management of TB in Uganda
Tuberculosis, Pulmonary
Primary: Difference in 7-day Treatment Initiation From Pre-implementation to Post-implementation — 1; -13 percentage of participants
Phase 2 N=67 Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults
Muscle Atrophy · Quality of Life
Primary: MRI Quadriceps Involved Leg — 43.87; 38.31 AU — p=.03
Phase 3 N=322 Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Primary: Event-free Survival (EFS) Per Blinded Independent Review Committee (BIRC) Assessment — 3.0; 3.0 months — p== 0.694
N/A N=73 Daily Living Skills Intervention for Adolescents With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Vineland Adaptive Behavior Scales, 3rd Edition — 195.7; 201.7; 232.2; 227.9 Score on a scale
Phase 2 N=50 Teverelix Evaluated in Advanced Prostate Cancer
Prostatic Adenoma
Primary: Testosterone (T) Levels (Castrate) at Week 4 — 5; 39 Participants
Phase 2 N=61 A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
Parkinson Disease
Primary: Change in Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) Scores — -4.5714; -2.7665 units on a scale…
Phase 4 N=30 Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon
Cystic Fibrosis · Chronic Pancreatitis
Primary: Mean Change in Total Symptom Score (TSS) From Day 1 (Baseline) to Days 8, 15, 29, and 85 — 0.0012; 0.0480; 0.1506; 0.0791 score on a scale
N/A N=503 Identification and Treatment of Cervical Abnormalities in Perú Through Integration of Pocket Colposcopy and Telemedicine
Cervical Cancer · HPV Infection · HIV Infections
Primary: Number of HPV Positive Women Examined — 503 Participants
Phase 3 N=76 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Myelodysplastic Syndrome/Acute Myeloid Leukemia
Primary: Overall Survival (OS) (Phase II) — 6.2; 5.2; 7.4 months